Clearpoint Neuro (CLPT) Q3 2025 earnings summary

Executive summary

• Announced a strategic merger agreement to acquire IRRAS Holdings, Inc., expanding into neurocritical care and cranial irrigation markets, and enhancing operational scale with a combined commercial team of over 50 professionals.

• Revenue for Q3 2025 increased 9% year-over-year to $8.9 million, driven by growth in service revenue and neurosurgery navigation and therapy sales.

• Supported over 60 biopharma partners, with nine programs accepted for FDA expedited review and expanded global regulatory clearances to 34 countries.

• Transitioned to a two-part growth strategy: "fast forward" to penetrate existing billion-dollar markets and "essential everywhere" to build a new multi-billion-dollar neurodrug delivery market.

• Demonstrated a prototype Robotic Neuro-Navigation System and received FDA clearance for PRISM Laser Therapy System compatibility with 1.5T MRI, expanding addressable market.

Financial highlights

• Q3 2025 revenue was $8.9 million, up 9% year-over-year from $8.1 million in Q3 2024.

• Gross margin improved to 63% from 60% in the prior year quarter, driven by higher service margins and favorable product mix.

• Cash and equivalents stood at $38.2 million as of September 30, 2025, up from $20.1 million at year-end 2024, reflecting $32 million in new financing offset by $11.8 million in operating cash use.

• Net loss for Q3 2025 was $5.9 million, compared to $5.0 million in Q3 2024, with net loss per share of $(0.21).

• Operating expenses increased 9% to $10.9 million, driven by R&D, professional services, and personnel costs.

Outlook and guidance

• 2025 full-year revenue forecast narrowed to $36–$38 million, in line with prior guidance.

• Post-merger, 2026 revenue for the combined entity expected between $54–$60 million, with further updates after integration.

• Biologics and drug delivery expected to return to double-digit growth in Q4 2025 and accelerate in 2026–2027.

• Cash reserves projected to be sufficient to support operations for at least the next twelve months.

• Long-term vision targets $500 million annual revenue and 70% gross margins.